Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Proteogenomics provides molecular insights into endometrial carcinoma

Key clinical point: A systematic proteogenomic analysis has revealed novel insights into the underlying molecular and immune mechanisms of endometrial carcinoma.

Major finding: The measurement of tumor antigen presentation defects could be more effective than measuring tumor mutation burden in the selection of immunotherapy for patients with endometrial carcinoma.

Study details: A multiomic analysis of 95 endometrial carcinoma tumor samples.

Disclosures: The study was funded by the National Cancer Institute, the Cancer Prevention & Research Institutes of Texas, and the Robert and Janice McNair Foundation. The authors reported having no conflicts of interest.

Citation:

Dou Y et al. Cell. 2020 Feb 13. doi: 10.1016/j.cell.2020.01.026.